Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 1
1996 1
1998 2
1999 1
2000 3
2001 1
2004 1
2008 2
2009 2
2010 1
2011 2
2012 1
2014 4
2015 2
2016 1
2017 2
2018 2
2020 4
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300.
Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-Ulloa A, Besada V, Ramos Y, Vázquez-Blomquist D, Caballero E, Aguilar D, González LJ, Zettl K, Wiśniewski JR, Yang K, Perera Y, Perea SE. Rosales M, et al. Among authors: perea se. Biomedicines. 2021 Jul 1;9(7):766. doi: 10.3390/biomedicines9070766. Biomedicines. 2021. PMID: 34356831 Free PMC article.
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
Cruz LR, Baladrón I, Rittoles A, Díaz PA, Valenzuela C, Santana R, Vázquez MM, García A, Chacón D, Thompson D, Perera G, González A, Reyes R, Torres L, Pérez J, Valido Y, Rodriguez R, Vázquez-Bloomquist DM, Rosales M, Ramón AC, Pérez GV, Guillén G, Muzio V, Perera Y, Perea SE; ATENEA-Co-300 Group. Cruz LR, et al. Among authors: perea se. ACS Pharmacol Transl Sci. 2020 Dec 11;4(1):206-212. doi: 10.1021/acsptsci.0c00175. eCollection 2021 Feb 12. ACS Pharmacol Transl Sci. 2020. PMID: 33615173 Free PMC article.
35 results